CN107746869A - 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 - Google Patents

微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 Download PDF

Info

Publication number
CN107746869A
CN107746869A CN201710860445.0A CN201710860445A CN107746869A CN 107746869 A CN107746869 A CN 107746869A CN 201710860445 A CN201710860445 A CN 201710860445A CN 107746869 A CN107746869 A CN 107746869A
Authority
CN
China
Prior art keywords
protein
ala
microalgal
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710860445.0A
Other languages
English (en)
Chinese (zh)
Inventor
A-C·V·贝恩
J·C·利普梅尔
K·E·埃普特
R·E·泽克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccine Technologies SAS
Original Assignee
Sanofi Vaccine Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Vaccine Technologies SAS filed Critical Sanofi Vaccine Technologies SAS
Publication of CN107746869A publication Critical patent/CN107746869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201710860445.0A 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 Pending CN107746869A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29046909P 2009-12-28 2009-12-28
US29044109P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12
CN201080064882.8A CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080064882.8A Division CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN107746869A true CN107746869A (zh) 2018-03-02

Family

ID=44307127

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710860445.0A Pending CN107746869A (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途
CN201080064882.8A Active CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080064882.8A Active CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Country Status (9)

Country Link
US (3) US20110189228A1 (https=)
EP (3) EP2519635B1 (https=)
JP (5) JP6339548B2 (https=)
CN (2) CN107746869A (https=)
AU (4) AU2010343095B2 (https=)
CA (3) CA3028175C (https=)
EA (1) EA022841B1 (https=)
IN (1) IN2012DN06277A (https=)
WO (1) WO2011090731A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109161576A (zh) * 2018-09-26 2019-01-08 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
CN111621471A (zh) * 2020-06-12 2020-09-04 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
CN114746553A (zh) * 2019-11-21 2022-07-12 松下知识产权经营株式会社 修饰蓝细菌、修饰蓝细菌的制造方法以及蛋白的制造方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324181B (en) 2001-04-16 2010-05-01 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
CN104263729B (zh) * 2009-03-16 2020-09-15 帝斯曼知识产权资产有限公司 在网粘菌门微生物中产生蛋白质
US10633667B2 (en) * 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
EP2519636B8 (en) * 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
WO2012120375A1 (en) * 2011-03-07 2012-09-13 Ocean Nutrition Canada Limited Engineering thraustochytrid microorganisms
US9404101B2 (en) * 2011-08-24 2016-08-02 Novozymes, Inc. Methods for obtaining positive transformants of a filamentous fungal host cell
DK2877576T3 (da) * 2012-07-24 2019-08-12 Bp Corp North America Inc Xyloseisomeraser og anvendelser deraf
US20150232900A1 (en) * 2012-09-18 2015-08-20 Myko Tech Private Limited Paper folding method and device for manufacturing filter cartridges
ES2873094T3 (es) * 2014-10-02 2021-11-03 Evonik Operations Gmbh Procedimiento para la producción de un pienso que contiene PUFAs mediante extrusión de una biomasa que contiene PUFAs de tipo Labyrinthulomycetes
FI3200604T4 (fi) 2014-10-02 2025-07-29 Evonik Operations Gmbh Menetelmä rehun valmistamiseksi
ES2870093T3 (es) 2014-10-02 2021-10-26 Evonik Operations Gmbh Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos
CA2958439C (en) 2014-10-02 2022-09-20 Evonik Industries Ag Feedstuff of high abrasion resistance and good stability in water, containing pufas
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
CA2991707C (en) * 2015-07-13 2023-08-01 MARA Renewables Corporation Enhancing microbial metabolism of c5 organic carbon
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
EP3512948A4 (en) * 2016-09-09 2020-05-13 Cornell University ADMINISTRATION OF NUCLEIC ACIDS, PROTEINS AND SMALL MOLECULES IN GLASS-LIKE VESICULAR BODIES
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CN109996810B (zh) * 2016-11-27 2023-08-22 特里同阿盖亚创新公司 从微藻中纯化重组骨桥蛋白的方法
EP3762485A4 (en) * 2018-03-05 2021-12-08 Conagen Inc. ORGANISMS AND METHOD FOR MANUFACTURING GLYCOMOLECULES WITH LOW SULFATION
AU2019293111A1 (en) 2018-06-27 2021-01-07 Sumitomo Electric Industries, Ltd. Original form body of flexible printed-wiring board, method of manufacturing flexible printed-wiring board, concentrated photovoltaic power generation module, and light emitting module
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
US20240287443A1 (en) * 2021-06-24 2024-08-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
WO2023079113A1 (en) 2021-11-05 2023-05-11 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
AU2022379948A1 (en) 2021-11-05 2024-06-20 Sanofi Pasteur Inc. Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
JP2024542635A (ja) 2021-11-30 2024-11-15 サノフィ パスツール インコーポレイテッド ヒトメタニューモウイルスワクチン
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
EP4525900A1 (en) 2022-06-14 2025-03-26 Hun-Ren Támogatott Kutatócsoportok Irodája Extracellular vesicles for use in therapy
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
CN1354792A (zh) * 1999-05-28 2002-06-19 爱尔基因泰克株式会社 用转化的微藻生物合成外源蛋白质
CN1556850A (zh) * 2001-04-16 2004-12-22 ��̩�������ѧ��˾ 转化破囊壶菌目微生物的产物和方法
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
WO2009101160A1 (en) * 2008-02-12 2009-08-20 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Production of glycosylated polypeptides in microalgae

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
JPH09511381A (ja) * 1994-01-11 1997-11-18 ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー インフルエンザワクチン
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US20060121447A1 (en) 2002-04-12 2006-06-08 Ilaria Capua Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005047501A1 (en) * 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
KR20060017635A (ko) * 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
JP4980895B2 (ja) * 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
JP4796786B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
KR101524398B1 (ko) * 2006-03-15 2015-06-04 디에스엠 아이피 어셋츠 비.브이. Ｐｕｆａ 폴리케티드 신타제 시스템을 이용한 이종 생물체내 다불포화 지방산의 제조
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009076778A1 (en) * 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
AU2009225652B2 (en) * 2008-03-19 2014-08-28 Momentive Specialty Chemicals Inc. Modifier for concrete and cement formulations and methods of preparing the same
CN104263729B (zh) * 2009-03-16 2020-09-15 帝斯曼知识产权资产有限公司 在网粘菌门微生物中产生蛋白质
US10633667B2 (en) * 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
EP2519636B8 (en) * 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
CN1354792A (zh) * 1999-05-28 2002-06-19 爱尔基因泰克株式会社 用转化的微藻生物合成外源蛋白质
CN1556850A (zh) * 2001-04-16 2004-12-22 ��̩�������ѧ��˾ 转化破囊壶菌目微生物的产物和方法
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
WO2009101160A1 (en) * 2008-02-12 2009-08-20 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Production of glycosylated polypeptides in microalgae

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GIUSEPPINA TURTURICI等: "Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages", 《AM J PHYSIOL CELL PHYSIOL》 *
MARKUS FUHRMANN: ""Production of Antigens in Chlamydomonas reinhardtii：Green Microalgae as a Novel Source of Recombinant Proteins"", 《METHODS IN MOLECULAR MEDICINE》 *
OLIVIER GASSER等: "Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils", 《EXPERIMENTAL CELL RESEARCH》 *
TARA L.等: ""Microalgae as bioreactors"", 《PLANT CELL REP》 *
YOKO SHOJI等: ""Plant-expressed HA as a seasonal influenza vaccine candidate"", 《VACCINE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109161576A (zh) * 2018-09-26 2019-01-08 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
CN114746553A (zh) * 2019-11-21 2022-07-12 松下知识产权经营株式会社 修饰蓝细菌、修饰蓝细菌的制造方法以及蛋白的制造方法
CN111621471A (zh) * 2020-06-12 2020-09-04 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法

Also Published As

Publication number Publication date
CN102822343B (zh) 2017-10-20
CA2785971A1 (en) 2011-07-28
EP2519635A1 (en) 2012-11-07
AU2022203980B2 (en) 2024-12-12
JP2023101420A (ja) 2023-07-20
JP6339548B2 (ja) 2018-06-06
CA3028175C (en) 2022-05-24
CA3028175A1 (en) 2011-07-28
US20150110826A1 (en) 2015-04-23
JP6666950B2 (ja) 2020-03-18
JP7585382B2 (ja) 2024-11-18
JP2018121660A (ja) 2018-08-09
AU2010343095B2 (en) 2017-01-05
AU2017202195A1 (en) 2017-04-20
JP2013515503A (ja) 2013-05-09
EP2519635A4 (en) 2013-06-26
AU2019206054B2 (en) 2022-03-10
EA022841B1 (ru) 2016-03-31
US20200063174A1 (en) 2020-02-27
EP4130273B1 (en) 2024-06-12
AU2010343095A1 (en) 2012-08-09
EP3505632B1 (en) 2022-08-03
WO2011090731A1 (en) 2011-07-28
US20110189228A1 (en) 2011-08-04
AU2022203980A1 (en) 2022-06-30
JP2016047055A (ja) 2016-04-07
IN2012DN06277A (https=) 2015-09-25
EP3505632A1 (en) 2019-07-03
EA201290567A1 (ru) 2013-02-28
JP5838496B2 (ja) 2016-01-06
JP2025114812A (ja) 2025-08-05
JP7745996B2 (ja) 2025-09-30
AU2019206054A1 (en) 2019-08-08
CA3153553A1 (en) 2011-07-28
EP4130273A1 (en) 2023-02-08
EP2519635B1 (en) 2018-11-21
CA2785971C (en) 2019-02-12
CN102822343A (zh) 2012-12-12
EP4130273C0 (en) 2024-06-12
AU2017202195B2 (en) 2019-04-18
JP2020096635A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
JP7585382B2 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
CN110656123B (zh) 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用
CN110029096B (zh) 一种腺嘌呤碱基编辑工具及其用途
KR101939014B1 (ko) 라비린툴로바이코타문 미생물에서의 단백질 생산
KR102863167B1 (ko) 클로스트리듐 박테리아의 형질전환을 위한 유전자 도구
KR102092422B1 (ko) 유전자 조작된 미생물로부터 뮤콘산의 생산
US6773920B1 (en) Delivery of functional protein sequences by translocating polypeptides
KR20210125560A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴
KR20210139265A (ko) 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법
KR102823029B1 (ko) 알파바이러스 레플리콘 입자
KR20210124280A (ko) 표적-이탈 탈아미노화가 감소된 핵염기 편집기 및 이를 이용하여 핵염기 표적 서열을 변형시키는 방법
KR20210127206A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용하여 질환-관련 유전자를 편집하는 방법
CN112680434B (zh) 一种提高蛋白质谷氨酰胺酶分泌表达的方法
CN112996536B (zh) 具有异源刺突蛋白的h52 ibv疫苗
DK2713712T3 (en) TRANSGEN CHICKEN, INCLUDING AN INACTIVATED IMMUNGLOBULIN GENE
CN107858297A (zh) 在蔗糖上生长的重组破囊壶菌和其组合物、制备方法及用途
CN114836443B (zh) 重组柯萨奇病毒a10 vlp及其用途
CN113186140B (zh) 用于预防和/或治疗宿醉和肝病的基因工程细菌
KR20230157342A (ko) 다중 치환기 실로시빈 유도체 및 사용 방법
KR102335519B1 (ko) 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물
KR20180038462A (ko) 재조합 세포, 재조합 세포의 제조 방법, 및 1,4-부탄디올의 생산 방법
RU2795596C2 (ru) Частица репликона альфавируса
CN113151311A (zh) 一种表达hpv 59l1的多核苷酸及其表达载体、宿主细胞和应用
RU2766680C1 (ru) Новые варианты гиалуронидазы и содержащая их фармацевтическая композиция
Klocek Elimination of Leishmania RNA virus from Leishmania spp. via expression of homologous viral capsid proteins: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biological Sciences at Massey University, Palmerston North, New Zealand

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination